Department of Large Animal Clinical Sciences, Center for Molecular Medicine and Infectious Diseases, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061-0342, USA.
Vaccine. 2012 Feb 14;30(8):1502-12. doi: 10.1016/j.vaccine.2011.12.036. Epub 2012 Jan 9.
Brucellosis is worldwide zoonoses affecting 500,000 people annually with no approved human vaccines available. Live attenuated Brucella abortus vaccine strain RB51 protects cattle through CD4 and CD8 T-cell mediated responses. However, limited information is known regarding how Brucella stimulate innate immunity. Although the most critical toll like receptors (TLRs) involved in the recognition of Brucella are TLR2, TLR4 and TLR9, it is important to identify the essential TLRs that induce DC activation/function in response to Brucella, to be able to upregulate both vaccine strain RB51-mediated protection, and clearance of pathogenic strain 2308. Furthermore, in spite of the importance of aerosol transmission of Brucella, no published studies have addressed the role of TLRs in the clearance of strain 2308 or strain RB51 from intranasally infected mice. Therefore, we used a (a) bone marrow derived dendritic cell model in TLRKO and control mice to assess the differential role of pathogenic and vaccine strains to induce DC activation and function in vitro, and (b) respiratory model in TLRKO and control mice to assess the critical roles for TLRs in clearance of strains in vivo. In support of the essential TLRs in clearance and protection, we performed challenge experiments to identify if these critical TLRs (as agonists) could enhance vaccine induced protection against pathogenic strain 2308 in a respiratory model. We determined: vaccine strain RB51 induced significant (p≤0.05) DC activation vs. strain 2308 which was not dependent on a specific TLR; strain RB51 induced TNF-α production was TLR2 and TLR9 dependent, and IL-12 production was TLR2 and TLR4 dependent; TLR4 and TLR2 were critical for clearance of vaccine and pathogenic Brucella strains respectively; and TLR2 (p<0.05), TLR4 (p<0.05) and TLR9 (p=0.075) agonists enhanced vaccine strain RB51-mediated protection against respiratory challenge with strain 2308 in the lung.
布鲁氏菌病是一种全球性的动物传染病,每年影响 50 万人,目前尚无可用的人类疫苗。活减毒布鲁氏菌流产疫苗株 RB51 通过 CD4 和 CD8 T 细胞介导的反应来保护牛。然而,关于布鲁氏菌如何刺激先天免疫,人们知之甚少。尽管参与布鲁氏菌识别的最重要的 toll 样受体 (TLRs) 是 TLR2、TLR4 和 TLR9,但确定诱导 DC 激活/功能的关键 TLR 对于上调疫苗株 RB51 介导的保护和清除致病性菌株 2308 非常重要。此外,尽管布鲁氏菌气溶胶传播非常重要,但目前尚无研究探讨 TLR 在清除鼻腔感染的 2308 或 RB51 菌株中的作用。因此,我们使用(a)TLRKO 和对照小鼠的骨髓来源树突状细胞模型来评估致病性和疫苗株在体外诱导 DC 激活和功能的差异作用,以及(b)TLRKO 和对照小鼠的呼吸模型来评估 TLR 在体内清除菌株中的关键作用。为了支持清除和保护的关键 TLR,我们进行了挑战实验,以确定这些关键 TLR(作为激动剂)是否可以增强疫苗对呼吸道模型中致病性菌株 2308 的诱导保护作用。我们确定:疫苗株 RB51 诱导的 DC 激活显著(p≤0.05)高于菌株 2308,而不依赖于特定的 TLR;RB51 株诱导 TNF-α 的产生依赖于 TLR2 和 TLR9,而 IL-12 的产生依赖于 TLR2 和 TLR4;TLR4 和 TLR2 分别是清除疫苗和致病性布鲁氏菌株的关键;TLR2(p<0.05)、TLR4(p<0.05)和 TLR9(p=0.075)激动剂增强了疫苗株 RB51 对肺部 2308 株呼吸道挑战的介导保护作用。